Top Markets
Coin of the day
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Classifica tra le azioni #25837
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Prezzo delle azioni
$0.74834668
Capitalizzazione di mercato
$45.86M
Variazione (1 giorno)
-0.15%
Variazione (1 anno)
-6.28%
Paese
SE
Scambia Mendus AB (publ) (IMMU)

Categoria

Storico del prezzo dell'azione per Mendus AB (publ) (IMMU)
Prezzo di chiusura più alto: $0.75 il 2026-08-01

Prezzo di chiusura più basso: $1.01 il 2013-04-01
Storico del prezzo dell'azione di Mendus AB (publ) dal 2013 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 14.30%
2025 -29.72%
2024 -32.55%
2023 -76.95%
2022 -39.21%
2021 -55.05%
2020 -17.38%
2019 29.23%
2018 -11.66%
2017 -59.00%
2016 -42.62%
2015 63.38%
2014 -42.62%
2013 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$539.14 35.65%
US
$1.04K 56.21%
NL
$120.74 -16.83%
AU
$761.87 8.65%
CH
$130.43 397.46%
US